New targeted epigenetic therapy for lymphoma shows promise

New compounds targeting epigenetics have shown promise in treating patients with lymphoma, according to data presented at the Targeted Anticancer Therapies International Congress 2018 in Paris, France. ESMO’s phase-I oncology meeting featured early clinical studies with BET inhibitors and EZH2 inhibitors. Dr. Anastasios Stathis, head of the New Drugs Development Unit of the Oncology Institute … Continue reading New targeted epigenetic therapy for lymphoma shows promise